Zobrazeno 1 - 10
of 620
pro vyhledávání: '"Jeffrey S, Weber"'
Autor:
Fatima Bawany, MD, Vignesh Ramachandran, MD, Eduardo Rodriguez, MD, Randie H. Kim, MD, Jeffrey S. Weber, MD, Ian W. Tattersall, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 41, Iss , Pp 7-9 (2023)
Externí odkaz:
https://doaj.org/article/571264ec4a364c9d915d6f844ff0e527
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox, Thomas F. Gajewski, Jérôme Galon, Claus Garbe, Brian R. Gastman, Jeffrey E. Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S. Leidner, Roger S. Lo, Alexander M. Menzies, Olivier Michielin, Poulikos I. Poulikakos, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) o
Externí odkaz:
https://doaj.org/article/06bb97ac823040b3bb11134f118a0c11
Autor:
Pankti Reid, Sabina Sandigursky, Juhee Song, Maria A. Lopez-Olivo, Houssein Safa, Samuel Cytryn, Elizaveta Efuni, Maryam Buni, Anna Pavlick, Michelle Krogsgaard, Osama Abu-Shawer, Mehmet Altan, Jeffrey S. Weber, Osama E. Rahma, Maria E. Suarez-Almazor, Adi Diab, Noha Abdel-Wahab
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTPatients with preexisting autoimmune disease (pAID) are generally excluded from clinical trials for immune checkpoint inhibitors (ICIs) for cancer due to concern of flaring pAID. In this multi-center, retrospective observational study, we com
Externí odkaz:
https://doaj.org/article/e9e4bf95dfc442469304d1d2730ac304
Autor:
Wolfram Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2378-2388 (2023)
Abstract Background Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. Methods This retrospective observational study utilized
Externí odkaz:
https://doaj.org/article/af40e545f9924238b22b08dd911e1b09
Autor:
Ariel Isser, Aliyah B. Silver, Hawley C. Pruitt, Michal Mass, Emma H. Elias, Gohta Aihara, Si-Sim Kang, Niklas Bachmann, Ying-Yu Chen, Elissa K. Leonard, Joan G. Bieler, Worarat Chaisawangwong, Joseph Choy, Sydney R. Shannon, Sharon Gerecht, Jeffrey S. Weber, Jamie B. Spangler, Jonathan P. Schneck
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Adoptive cell therapies (ACT) hold promise for cancer immunotherapy, but optimization is still an ongoing process. Here the authors report CD4-targeted, nanoparticle-based artificial antigen-presenting cells that expand CD4+ T cells capable of lysing
Externí odkaz:
https://doaj.org/article/e2e34112c5114ce1ab987cad006bc54e
Autor:
Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background The phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients with advanced solid tumors.Methods GSK3
Externí odkaz:
https://doaj.org/article/cede222f65c649b89ade485245fc9ae7
Autor:
Mykhaylo Usyk, Abhishek Pandey, Richard B. Hayes, Una Moran, Anna Pavlick, Iman Osman, Jeffrey S. Weber, Jiyoung Ahn
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-11 (2021)
Abstract Background Immune checkpoint blockade (ICB) shows lasting benefits in advanced melanoma; however, not all patients respond to this treatment and many develop potentially life-threatening immune-related adverse events (irAEs). Identifying ind
Externí odkaz:
https://doaj.org/article/eb0398ba76174efe9970f48be8edadbe
Autor:
Paolo A. Ascierto, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Abstract The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immuni
Externí odkaz:
https://doaj.org/article/a6ed1cc2e48e427fb2e3f34087eb34fc
Autor:
Saurabh K. Garg, James Sun, Youngchul Kim, Junmin Whiting, Amod Sarnaik, José R. Conejo-Garcia, Mitch Phelps, Jeffrey S. Weber, James J. Mulé, Joseph Markowitz
Publikováno v:
Cancers, Vol 15, Iss 6, p 1755 (2023)
Although Ipilimumab (anti-CTLA-4) is FDA-approved for stage III/IV melanoma adjuvant treatment, it is not used clinically in first-line therapy, given the superior relapse-free survival (RFS)/toxicity benefits of anti-PD-1 therapy. However, it is imp
Externí odkaz:
https://doaj.org/article/d18b7a0edc5a4666a20d6d4119927845
Autor:
Brandilyn A. Peters, Melissa Wilson, Una Moran, Anna Pavlick, Allison Izsak, Todd Wechter, Jeffrey S. Weber, Iman Osman, Jiyoung Ahn
Publikováno v:
Genome Medicine, Vol 11, Iss 1, Pp 1-14 (2019)
Abstract Background Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expres
Externí odkaz:
https://doaj.org/article/6c3d4a5a7b3147f19474d1c8912c2453